Special Issue

Critical Advances in the Diagnosis and Treatment of High-Grade Gliomas

Message from the Guest Editors

Outcomes for pediatric and adult patients with highgrade gliomas remain dismal, despite aggressive surgical resection(s) and/or adjuvant radiation/chemotherapy. These poor clinical outcomes are driven, in part, by tumor heterogeneity, genetic mutations/alterations, and immunosuppressive tumor microenvironments. Accordingly, this Special Issue will attempt to highlight recent advances in the field, ranging from early preclinical to clinical. We also encourage the submission of translational papers in both the therapeutic and diagnostic space and are eager to review those, with a focus on novel targeted therapies and/or immunotherapies. We also encourage clinicians to submit articles describing innovative diagnostic modalities (e.g., both molecular and radiologic) and welcome analyses centered on clinical data. Surgeons are encouraged to submit their experiences related to resection, the use of advanced imaging, and/or the delivery of local experimental therapeutics. Finally, pertinent reviews related to such topics are also encouraged, in an effort to summarize the current status in the field and future directions.

Guest Editors

Dr. Timothy R. Smith

Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

Dr. Joshua D. Bernstock

Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

Deadline for manuscript submissions

closed (17 October 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/133829

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

